| Nov 21 |
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
|
| Oct 28 |
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
|
| Oct 28 |
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
|
| Oct 24 |
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
|
| Oct 15 |
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
|
| Oct 9 |
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
|
| Oct 7 |
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
|
| Sep 24 |
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
|
| Sep 24 |
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
|
| Aug 7 |
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
|
